June 3, 2021

Afimmune Announces Positive Data with Epeleuton from Preclinical Atherosclerosis Studies

Data show large decreases in atherosclerotic plaque following treatment with epeleuton Dublin, Ireland, 3rd June 2021 – Afimmune, a clinical stage drug discovery company focused on […]
December 15, 2020

Epeleuton and the potential of next generation Omega-3 fatty acids is discussed in the December 2020 edition of Pharmaceutical Market Europe

The article can be found below.   Treatment and prevention of cardiovascular disease The potential of next generation omega-3 fatty acids In 2019 approximately 17.3 million […]
September 23, 2020

Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes

Data from Phase IIa show potent effect of Epeleuton on Triglyceride and HbA1C levels Dublin, Ireland, 23rd September 2020 – Afimmune, a clinical stage drug discovery […]
November 14, 2019

Clinical Data Showing The Potential Of Epeleuton As A Treatment For Hypertriglyceridemia And Diabetes As Well As Cardiovascular Disease Prevention Will Be Presented At The American Heart Association’s 2019 Scientific Sessions, November 16-18

Dublin, Ireland, 14th November 2019 – Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
December 18, 2018

Afimmune receives method of use patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]